Single‐ and Multiple‐Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene‐Related Peptide Receptor Antagonist, in Adults

Telcagepant is a novel, orally active, and selective calcitonin gene‐related peptide receptor antagonist being developed for acute treatment of migraine with and without aura. Three separate clinical studies were conducted to evaluate the pharmacokinetics and tolerability of telcagepant following single oral doses in healthy young and elderly men and women and multiple oral doses in men. Telcagepant was rapidly absorbed with a time to maximum concentration of approximately 1.5 hours. The terminal half‐life was approximately 6 hours. A greater than dose‐proportional increase was observed in the area under the plasma concentration versus time curve from zero to infinity. Following twice‐daily dosing, with each dose separated by 2 hours, steady state was achieved in approximately 3 to 4 days with an accumulation ratio of approximately 2. There were no clinically meaningful pharmacokinetic differences when compared across age and gender. Telcagepant was generally well tolerated up to single doses of 1200 mg and multiple doses of 400 mg twice daily.

[1]  R. Nardin RANDOMIZED, CONTROLLED TRIAL OF TELCAGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE , 2010, Neurology.

[2]  E. Woolf,et al.  Elimination of diastereomer interference to determine Telcagepant (MK-0974) in human plasma using on-line turbulent-flow technology and off-line solid-phase extraction coupled with liquid chromatography/tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  R. Lipton,et al.  The epidemiology, burden, and comorbidities of migraine. , 2009, Neurologic clinics.

[4]  David W Dodick,et al.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial , 2008, The Lancet.

[5]  B. Wong,et al.  Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  S. Tepper,et al.  Clinical and Preclinical Rationale for CGRP‐Receptor Antagonists in the Treatment of Migraine , 2008, Headache.

[7]  P. Durham Inhibition of Calcitonin Gene‐Related Peptide Function: A Promising Strategy for Treating Migraine , 2008, Headache.

[8]  C Furtek,et al.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine , 2008, Neurology.

[9]  A. W. Shaw,et al.  Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of , 2008, Journal of Pharmacology and Experimental Therapeutics.

[10]  L. Edvinsson,et al.  Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system , 2008, The Journal of Headache and Pain.

[11]  A. W. Shaw,et al.  Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). , 2007, Journal of medicinal chemistry.

[12]  R. Lipton,et al.  The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide , 2007, Cephalalgia : an international journal of headache.

[13]  S. Hahn,et al.  Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of Migraine , 2004, Headache.

[14]  J. Olesen,et al.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. , 2004, The New England journal of medicine.

[15]  L. Edvinsson New therapeutic target in primary headaches – blocking the CGRP receptor , 2003, Expert opinion on therapeutic targets.

[16]  P. Goadsby,et al.  Vasoactive peptide release in the extracerebral circulation of humans during migraine headache , 1990, Annals of neurology.